Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390724 · ClinicalTrials.gov registry record
Optimizing Y90 Therapy for Radiation Lobectomy
A clinical trial of Metastatic Cancer and HCC, sponsored by Northwestern University.
- Recruiting
- Registry status
- 104
- Enrollment target
- 1
- Study location
NCT04390724: Recruiting study of Metastatic Cancer and HCC, sponsored by Northwestern University.
NCT04390724 is a study of Metastatic Cancer and HCC that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 104 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04390724, a study of Metastatic Cancer and HCC, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.
Primary Outcome
Measure the distribution of Y90 glass microspheres throughout the tumor and non-tumor hepatic parenchyma, as assessed by same day post-radioembolization study-specific non-FDG PET/CT scan.
Conditions Studied
Interventions
- DEVICE Y90 radioembolization
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2026-07 |
What NCT04390724 shows while recruiting
NCT04390724 is an observational study that tracks outcomes without assigning an intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (77% lower).
The record links to 5 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Y90 radioembolization is the first listed.
NCT04390724 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04390724 about?
NCT04390724 is a clinical study titled "Optimizing Y90 Therapy for Radiation Lobectomy". HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and emboli...
What is the current status of trial NCT04390724?
This trial is currently recruiting. The enrollment target is 104 participants. The study started on 2020-07-17. Estimated completion is 2026-07.
What conditions does trial NCT04390724 study?
This clinical trial studies the following conditions: Metastatic Cancer, HCC, Transplant, Adult Primary Liver Cancer, Resection.
What interventions are being tested in trial NCT04390724?
The interventions under investigation include: Y90 radioembolization (DEVICE).
Who is sponsoring clinical trial NCT04390724?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04390724 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04390724's enrollment target sits among peer trials
104 40th of 109 higher than 70 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT05064280 · 104 participants · Phase 2
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI